GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]

4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort Mumbai-400001
Email ID: corp.relations@bseindia.com

Dated: 06.12.2019

Ref: Genomic Valley Biotech Limited (539206/ GVBL)
Sub: Additional Announcement relating to Compliance under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Filing of Un-Audited Financial Results for the Quarter and Half Year ended 30th September, 2019.

Dear Sir/Madam,

Additional announcement relating With reference to the captioned subject and pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the Un-Audited Financial Results of the Company for the Quarter and Half Year ended 30th September, 2019 duly approved by the Board of Directors of the Company, at its meeting held on the 12th day of November, 2019. The Meeting of Board of Directors of the Company commenced at 11:45 A.M. and concluded at 02:35 P.M. We rectified the Cash Flow Statement for Standalone Results and also attached the extract for quarterly and yearly Financial Results.

We are also enclosing a copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We hereby kindly request you to take the same into your records**.**

Thanking you.
Yours faithfully,

GENOMIC VALLEY BIOTECH LTD. BAHADURGARH

For and on behalf of
Genomic Valley Biotech Limited
Sunil Kumar
Company Secretary & Compliance officer

Enclosed: A/A

GENOMIC VALLEY BIOTECH LIMITED

Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,

TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

Genomic Valley Biotech Limited today reported its financial performance for the quarter and six months ended 30 September 2019

Highlights of the Un-Audited Financial Results as compared to the previous year are:

In Rs.

Sr. No.	Particular	3 months ended 30-Sep-19 Un-Audited	Preceding 3 months ended 30-Jun-19 Un-Audited	Corresponding 3 months ended in the previous year 30-Sep-18 Un-Audited	Year to date figures for current period ended 30-Sep-19 Un-Audited	Year to date figures for corresponding period ended 30-Sep-18 Un-Audited	Previous year ended 31-Mar-19 Audited
I	Revenue From Operations	18,12,800	18,80,329	20,12,512	36,93,129	41,20,707	98,50,101
II	Other Income	1,22,504	3,165	-	1,25,669	-	1,47,952
III	**Total Revenue (I+II)**	**19,35,304**	**18,83,494**	**20,12,512**	38,18,799	**41,20,707**	**99,98,053**
					-		
IV	**Expenses**				-		
	Cost of materials consumed	0	16,265	1,03,645	16,265	1,50,761	4,71,545
	Purchases of Stock-in-Trade	-	-	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-	-
	Employee benefits expense	3,65,892	9,21,867	8,80,023	12,87,759	17,72,667	26,68,923
	Financial costs	-	-	-	-	-	-
	Depreciation and amortization expense	3,34,578	4,72,223	4,63,360	8,06,801	9,26,720	19,37,408
	Other expenses	10,13,781	3,61,276	4,63,977	13,75,057	11,03,588	25,73,127
	Total Expenses (IV)	**17,14,251**	**17,71,631**	**19,11,005**	**34,85,882**	**39,53,736**	**76,51,004**
V	**Profit / (Loss) before exceptional item and tax (III-IV)**	**2,21,053**	**1,11,864**	**1,01,507**	**3,32,917**	**1,66,971**	**23,47,049**
VI	**Exceptional item**	-	-	-	-	-	-
VII	**Profit/loss before Tax (V-VI)**	**2,21,053**	**1,11,864**	**1,01,507**	**3,32,917**	**1,66,971**	**23,47,049**
VIII	**Tax expenses**						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	22,083
IX	**Profit/ (Loss) for the period from continuing operations (VII-VIII)**	**2,21,053**	**1,11,864**	**1,01,507**	**3,32,917**	**1,66,971**	**23,24,966**
X	**Profit/ (Loss) from discontinued operations**	-	-	-	-	-	-
XI	**Tax expense of discontinued operations**	-	-	-	-	-	-
XII	**Profit/ (Loss) from discontinuing operations (after tax) (X-XI)**	-	-	-	-	-	-
XIII	**Profit/Loss for the period (IX+XII)**	**2,21,053**	**1,11,864**	**1,01,507**	**3,32,917**	**1,66,971**	**23,24,966**
XIV	**Other Comprehensive Income**						
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	**Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)**	**2,21,053**	**1,11,864**	**1,01,507**	**3,32,917**	**1,66,971**	**23,24,966**
XVI	**Paid up Equity Share Capital, Equity Share of ₹ 10/- each**	**30,54,500**	**30,54,500**	**30,54,500**	**30,54,500**	**30,54,500**	**30,54,500**
XVII	**Earning Per Equity Share (for continuing operation):**						
	1) Basic	0.07	0.04	0.03	0.11	0.05	0.76
	2) Diluted	0.07	0.04	0.03	0.11	0.05	0.76
XVIII	**Earning Per Equity Share (for discontinued operation):**						
	1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIX	**Earning Per Equity Share (for discontinued & continuing operations):**						
	1) Basic	0.07	0.04	0.03	0.11	0.05	0.76
	2) Diluted	0.07	0.04	0.03	0.11	0.05	0.76

GENOMIC VALLEY BIOTECH LTD. * BAHADURGARH *

Statement of Asset and Liabilities

Particulars	Current half year ended 30-09-2019 Un-Audited Standalone	Previous year ended 31-03-2019 Audited Standalone
ASSETS		
Non Current Assets		
Property, plant and equipment	428,08,346	430,77,029
Capital work in progress	48,79,339	48,85,459
Other Intangible assets	1,87,431	-
Intangible assets under development	-	-
Financial assets	-	-
Investment	-	-
Loans	256,00,000	206,00,000
Security Deposits	2,00,000	2,00,000
Other financial assets	-	-
Deferred tax assets (Net)	-	-
Other non current assets	-	-
Total Non-Current Assets	**736,75,116**	**687,62,488**
Current Assets		
Inventories	12,23,548	11,87,441
Financial Assets:	-	-
Investments	-	-
Trade Receivables	5,13,482	5,83,483
Cash and Cash equivalents	1,17,440	30,820
Other Balances with banks	38,683	7,19,824
Loans	-	-
Other financial assets	-	-
Other Current assets	8,27,691	4,91,181
Total Current Assets	**27,20,843**	**30,12,749**
Total Assets	**763,95,959**	**717,75,237**
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	305,45,000	305,45,000
Othe Equity	173,98,149	170,65,232
Total Equity	**479,43,149**	**476,10,232**
Non Current Liabilities		
Financial liabilities		
Borrowings	147,88,077	147,88,077
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	1,49,433	1,49,433
Provisions	-	-
Other Non Current liabilities	84,00,000	85,00,000
Total Non Current Liabilities	**233,37,510**	**234,37,510**
Current Liabilities		
Financial liabilities		
Borrowings	-	-
Trade Payables	1,57,257	47,474
Other Financials liabilities	-	-
Provisions	76,860	2,76,370
Other Current liabilities	48,81,182	4,03,650
Total Current Liabilities	**51,15,300**	**7,27,494**
TOTAL EQUITY AND LIABILITIES	**763,95,959**	**717,75,237**

GENOMIC VALLEY BIOTECH LTD. * BAHADURGARH *

Notes :

1 The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on November 12, 2019. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.

2 The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministery of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Comapnies Act, 2013 and other accounting principles generally accepted in India.

3 Company's Business activity falls within a single business segment i.e. Floriculture in terms of Ind-AS 108 on Segment Reporting.

4 Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited

GENOMIC VALLEY BIOTECH LTD. BAHADURGARH

Yogesh Agrawal
(Managing Director)
DIN-01165288
Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063

Place : Delhi
Dated : 12-11-2019

GENOMIC VALLEY BIOTECH LIMITED

REGD. OFF: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30 SEPTEMBER, 2019

	Particulars	Amount in INR		
		30.09.2019	30.09.2018	31.03.2019
A.	**CASH FLOW FROM OPERATING ACTIVITIES**			
	Net Profit As Statement Profit & Loss	**3,32,917**	**1,66,971**	**23,47,049**
	Adjustment For			
	Discount received	318		
	Non Operating Income	-	-	-1,39,000
	Interest Income	-21,851	-	-8,579
	Loss on sale of assets	-	-	-
	Depreciation and Amortisation Expenses	8,06,801	9,26,720	19,37,408
	Operating Profit Before Change in Working Capital	**11,17,549**	**10,93,691**	**41,36,877**
	ADJUSTMENTS FOR WORKING CAPITAL:			
	Increase/Decrease in Loans and Advances	-50,00,000	-1,50,000	-
	Decrease/ (Increase) in Inventories	-36,107	-83,301	-8,55,643
	Increase/Decrease in Security Deposits	-	-1,50,000	87,788
	Increase/Decrease in Trade Receivables	70,001	-5,06,864	-3,52,360
	Increase/Decrease in Other Current Assets	-3,36,510	34,123	2,84,905
	Increase/Decrease in Current Liabilities	43,87,806	13,71,872	-131,02,464
	CASH GENERATED FROM OPERATIONS	**2,02,739**	**16,09,521**	**-103,70,707**
	Taxes Paid		-	-
	Total (A)	**2,02,739**	**16,09,521**	**-103,70,707**
B.	**CASH FLOW FROM INVESTING ACTIVITIES**			
	Additions/Sales to fixed assets	-7,19,429	-16,30,764	35,72,223
	Purchase/Sell of Investments	-	-	-
	Discount received	318	-	-
	Non Operating Income	-	-	1,39,000
	Interest Income	21,851	-	8,579
	Total (B)	**-6,97,260**	**-16,30,764**	**37,19,803**
C.	**CASH FLOWS FROM FINANCING ACTIVITIES**			
	Proceeds from Borrowings	-1,00,000	-	72,88,077
	Preliminary Expenses	-	-	-
	Total (C)	**-1,00,000**	-	**72,88,077**
	NET CASH FLOWS DURING THE YEAR (A+B+C)	**-5,94,521**	**-21,242**	**6,37,173**
	Cash and Cash Equivalents (Opening Balance)	**7,50,644**	**1,13,472**	**1,13,472**
	Cash and Cash Equivalents (Closing Balance)	**1,56,123**	**92,230**	**7,50,644**

GENOMIC VALLEY BIOTECH LTD. * BAHADURGARH *

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901,
Email:cabhavukgarg@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil-Bahadurgarh, District-Jhajjar, Haryana-124507.

Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter and Half Year ended on 30th September, 2019

We have reviewed the accompanying statement of unaudited financial results for **the quarter and half year ended September 30, 2019** ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ANDROS & CO.
Chartered Accountants

ANDROS & CO. FRN : 08976N NEW DELHI Chartered Accountants

(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)
UDIN: 19502310AAAANW8780

Place: Delhi
Date: 12.11.2019

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman,
P.O. Tandaheri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507
CIN: L01122HR1994PLC033029 ; Tele: +91-9811341542
Email: genomicvalley@gmail.Com; Visit: http://www.genomicvalley.com

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019

(Amount in ₹)

Sr. No.	Particular	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Half Year Ended		Previous year ended
		30-Sep-19	30-Jun-19	30-Sep-18	30-Sep-19	30-Sep-18	31-Mar-19
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Tota income from operation	19,35,304	18,83,494	20,12,512	38,18,799	41,20,707	99,98,052
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Item)	2,21,053	1,11,864	1,01,507	3,32,917	1,66,971	23,47,049
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Item)	2,21,053	1,11,864	1,01,507	3,32,917	1,66,971	23,47,049
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Item)	2,21,053	1,11,864	1,01,507	3,32,917	1,66,971	23,24,966
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,21,053	1,11,864	1,01,507	3,32,917	1,66,971	23,24,966
6	Equity Share Capital (30,54,500 Equity Shares @ Rs. 10 each)	30,54,500	30,54,500	30,54,500	30,54,500	30,54,500	30,54,500
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	170,65,232	170,65,232	147,40,266	170,65,232	147,40,266	170,65,232
8	Earnings Per Share						
	(a) Basic	0.07	0.04	0.03	0.11	0.05	0.76
	(b) Diluted	0.07	0.04	0.03	0.11	0.05	0.76

Notes :

1 The above extracts of Financial Results were reviewed by the Members of Audit Committee and were thereafter approved by the Board of Directors at their respective Meeting held on November 12, 2019.

2 The above is an extract of the detailed format of quarterly and yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly and year to date Financial Results are available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.genomicvalley.com).